CAMELLIA-TIMI 61

CAMELLIA-TIMI 61 was a multicenter, randomized, double-blind, placebo-controlled, parallel-group study in overweight and obese subjects with CV disease and/or multiple CV risk factors.

MAIN RESULTS:
Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients

PRESENTATIONS

CV Safety & Efficacy of Lorcaserin in Overweight and Obese Patients-Primary Results from CAMELLIA (Bohula ESC 2018)
Primary Results (Bohula, ESC 2018)
Renal Outcomes (Bohula, AHA 2018)

PUBLICATIONS

Interindividual Variability In Weight Loss With Lorcaserin: An Analysis From The CAMELLIA-TIMI 61 Study

Persistence Of Valvulopathy In The Camellia-Timi 61 Trial Of Lorcaserin In Obese Or Overweight Patients At Increased Cardiovascular Risk

Lorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 Trial

Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial

Design and Rationale for the Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients-Thrombolysis in Myocardial Infarction 61 (CAMELLIA-TIMI 61) Trial